Rhenman & Partners Asset Management AB Has $2.11 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX

Rhenman & Partners Asset Management AB cut its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 25.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 185,000 shares of the company’s stock after selling 64,336 shares during the period. Rhenman & Partners Asset Management AB owned 0.24% of Nurix Therapeutics worth $2,107,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. E Fund Management Co. Ltd. bought a new position in Nurix Therapeutics in the 1st quarter valued at $122,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Nurix Therapeutics in the second quarter worth about $141,000. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Nurix Therapeutics during the 1st quarter worth about $169,000. KLP Kapitalforvaltning AS lifted its position in Nurix Therapeutics by 38.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 15,400 shares of the company’s stock valued at $175,000 after purchasing an additional 4,300 shares during the period. Finally, Creative Planning bought a new position in shares of Nurix Therapeutics in the 2nd quarter valued at about $187,000.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 6,284 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $472,155.52. This trade represents a 14.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 4,087 shares of the business’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $12.80, for a total transaction of $52,313.60. Following the transaction, the insider owned 76,751 shares in the company, valued at approximately $982,412.80. The trade was a 5.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 13,501 shares of company stock valued at $171,305. Corporate insiders own 7.40% of the company’s stock.

Wall Street Analysts Forecast Growth

NRIX has been the subject of a number of recent research reports. HC Wainwright dropped their price target on shares of Nurix Therapeutics from $33.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, October 27th. Baird R W upgraded shares of Nurix Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 26th. Mizuho began coverage on Nurix Therapeutics in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $24.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, November 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $26.88.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $17.00 on Wednesday. The company has a market cap of $1.31 billion, a PE ratio of -5.72 and a beta of 2.30. The stock has a 50-day simple moving average of $11.19 and a 200 day simple moving average of $10.98. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $23.00.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The business had revenue of $7.89 million for the quarter, compared to the consensus estimate of $16.06 million. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.